Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Date:9/4/2007

PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced new results from a large study that demonstrate combination treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater urinary symptom improvement for men with enlarged prostate than either AVODART or tamsulosin monotherapy over 24 months. Three analyses from the study - Combination therapy with Avodart and tamsulosin (CombAT) - were presented today at the 29th annual meeting of the Societe Internationale d'Urologie in Paris.

In addition, one of three analyses presented -- a post hoc analysis -- showed that AVODART provides a pattern of increasing enlarged prostate symptom improvement over 24 months. Tamsulosin -- the most commonly prescribed medicine for the condition -- provided early symptom improvement, but this improvement plateaued from month three through 24.1 Common symptoms of enlarged prostate include nocturia, frequency and urgency, incomplete emptying, starting and stopping, and weak stream.

The CombAT study includes 4,800 men (combination therapy, n=1492; AVODART, n=1502; tamsulosin, n=1519) with moderate-to-severe enlarged prostate symptoms. All study participants received placebo for four weeks and then were randomized to receive AVODART and tamsulosin combination therapy, AVODART monotherapy, or tamsulosin monotherapy.

Enlarged prostate (also known as benign prostatic hyperplasia (BPH)), is a condition that affects 50 percent of men over the age of 50 and more than 90 percent of men over age 80. AVODART belongs to a class of medicines known as 5 alpha reductase inhibitors (5 ARIs), which shrink the prostate over time. Tamsulosin is an alpha blocker,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , CARTERSVILLE, Ga. ; June 2 ... Women (GASC) – Georgia ,s first fully ... minor gynecological surgeries in a true ... facility specializes in laparoscopic and other highly advanced, ...
... (Nasdaq: FHCO ) announced that it has fulfilled an order for 3.5 million ... World Cup. The 2010 World Cup will take place in The Republic of ... . , , , ... three million tickets to the games, is expected to flood the country with visitors. ...
Cached Medicine Technology:New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 3
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: